PhagoDAIRI: Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.
Study Details
Study Description
Brief Summary
Pilot non comparative study assessing the clinical control of infection of DAIR + SAT +NaCl and DAIR + SAT + Phages anti-Staphylococcus aureus in patients with Staphylococcus aureus Prosthetic Joint Infection with an indication of DAIR + SAT.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Bacteriophages arm 1 mL (PP1493 or PP1815) or 2 mL (PP1493 and PP1815) of suspension of bacteriophages diluted in solution of NaCl 0,9% at the end of DAIR procedure. |
Biological: Anti-Staphylococcus aureus Bacteriophages
Single intra-articular injection
|
| Placebo Comparator: Control Arm One local administration of NaCl 0,9% solution is administered at the end of the DAIR procedure. |
Biological: Anti-Staphylococcus aureus Bacteriophages
Single intra-articular injection
|
Outcome Measures
Primary Outcome Measures
- Clinical control of infection at week 12 visit [week 12 visit]
No Fever, no recurrence, no worsening of pain, no periarticular inflammatory and clinical infectious signs, no new surgical request, no Staphylococcus aureus detected in joint fluid.
Secondary Outcome Measures
- Adverse Events and Serious Adverse Events [From the time of signing the informed consent form up to study end visit (Months 24)]
Incidence, severity and type of adverse events and serious adverse events
- Clinical laboratory tests [From the time of signing the informed consent form up to study end visit (Months 24)]
Number of participants with abnormal clinical laboratory tests
- Physical examination [From the time of signing the informed consent form up to study end visit (Months 24)]
Number of participants with clinically abnormal physical examination findings
- Clinical control of infection after Week 12 visit [Month 6, Month 12, Month 18 and Month 24.]
No Fever, no recurrence, no worsening of pain, no periarticular inflammatory and clinical infectious signs, no new surgical request, no Staphylococcus aureus detected in joint fluid
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female ≥ 18 years
-
Staphylococcus aureus monomicrobial knee or hip PJI ˃3 months after prosthesis implantation with clinical signs of infection and with indication of DAIR with direct closure and Suppressive Antibiotics Therapy (SAT)
-
Staphylococcus aureus only in joint fluid within 6 months before randomization or in case of relapse of infection under antibiotics therapy after a DAIR performed within 6 months before pre-inclusion visit
-
Without preoperative diagnosis of superinfection due to another pathogen
-
Phagogram displaying the susceptibility of the strain to at least one of the phages.
-
Patient with a life expectancy of 2 years and more as determined by the principal investigator
-
Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration
-
Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months)
-
Negative pregnancy test
Exclusion Criteria:
-
Early Staphylococcus aureus Prosthesis Joint infection (˂3months after the prosthesis implantation)
-
Other germ found in culture of joint fluid sample
-
Phagogram displaying no susceptibility of the strain to anti-Staphylococcus aureus bacteriophages
-
Patients with ASA score ≥ 4
-
Severe sepsis or Septic shock or hemodynamic instability
-
Patients with an indication to prosthesis replacement or amputation
-
Immunosuppressed patients
-
ALT or AST > 5 x ULN, creatinine > 1.53 mg/dl in men and > 1.24 mg/dl in women
-
Known allergic reactions to components of phages products
-
Medical history which in the opinion of the investigator would mean that the patient is unsuitable for participation in the study
-
Patients who are pregnant or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
-
Women/Men refusing to use an effective contraception during 1 month after the last administration of study drug.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pr Tristan Ferry | Lyon | France | 69004 |
Sponsors and Collaborators
- Pherecydes Pharma
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-004469-11